Combination of bedaquiline, ethambutol, and macrolides in the treatment of nontuberculous mycobacterial disease
Patent Information
- Application Number
- JP2023528411
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-12
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-27
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for non-tuberculous mycobacterial (NTM) lung diseases, such as MAC-PD, are lengthy, have high failure rates, and limited alternative options, with bedaquiline's efficacy in NTM diseases needing further study.
A combination therapy using bedaquiline, a macrolide (e.g., clarithromycin or azithromycin), and optionally ethambutol, administered in specific regimens to treat NTM diseases, including NTM-PD, with potential inclusion of aminoglycosides for severe cases.
The combination therapy demonstrates improved efficacy and safety, reducing side effects and potential resistance, offering a more effective treatment option for NTM-PD, particularly in treatment-refractory patients.
Smart Images

Figure 00000025_0000 
Figure 00000025_0001 
Figure 00000025_0002
Abstract
Description
[Technical Field]
[0001] The present invention relates to a combination of drug components for use in treating diseases associated with nontuberculous mycobacteria, the combination comprising a first drug component that is bedaquiline (e.g., bedaquiline fumarate, commercially available as Sirturo®), a second drug component that is a macrolide (e.g., clarithromycin or azithromycin), and, optionally, a third drug component that has activity against nontuberculous mycobacteria (e.g., ethambutol). The combination may also include an aminoglycoside, such as an aminoglycoside (e.g., an injectable or inhalable aminoglycoside). [Background technology]
[0002] Nontuberculous mycobacterial (NTM) lung disease is a significant cause of morbidity and mortality among individuals with pre-existing pulmonary conditions such as bronchiectasis and chronic obstructive pulmonary disease (COPD).
[0003] Mycobacterium avium complex (MAC), Mycobacterium abscessus (MAB), and Mycobacterium kansasii are mycobacterium species that cause non-transplant pulmonary disease (NTM-PD). NTM-PD is distinct from the pulmonary infection caused by Mycobacterium tuberculosis. Mycobacterium avium is one of several individual species within MAC, accounting for up to 70% of NTM-positive sputum cultures (although this varies geographically). MAC species are common, naturally occurring organisms in water and soil, often colonizing natural water sources such as indoor water systems, hot tubs, and swimming pools. MAC-pulmonary disease (MAC-PD) is most frequently seen in postmenopausal women and patients with underlying lung disease (such as cystic fibrosis or bronchiectasis) or immunodeficiency. Clinical symptoms vary in scope and intensity but generally include a chronic cough, often accompanied by purulent sputum, although hemoptysis may also be present. Systemic symptoms include malaise, fatigue, and, in advanced disease, weight loss.
[0004] Current treatment for MAC-PD involves long-term antibiotic therapy (often >18 months) with a combination of at least three antibiotics, including rifamycin (rifampin or rifabutin), macrolide (azithromycin or clarithromycin), ethambutol, and / or aminoglycosides (especially injectable or inhalable), which is associated with side effects and a high failure rate. This treatment regimen is currently recommended by the American Thoracic Society (see Griffith et al., Am. J. Respir. Crit. Care Med., 2007, 175, 367-415) and international guidelines, given that the combination demonstrates in vitro and clinical activity against MAC. Recently, amikacin liposome inhalation suspension (ALIS, Arikayce®) was approved by the U.S. FDA for the treatment of MAC-PD in adults, but otherwise, this disease / condition has limited or no alternative treatment options. No other antibiotics have been approved for the treatment of MAC-PD, and the recommended use of these agents is solely empirical.
[0005] Bedaquiline, or (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol, is a mycobacterial adenosine 5'-triphosphate (ATP) synthase inhibitor developed as part of a combination therapy for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients. Bedaquiline is approved for this indication under the trade name Sirturo® in regions including the United States, Japan, Russia, the EU, South Africa, and the Republic of Korea, under certain conditions.
[0006] The commercially available bedaquiline product, Sirturo®, is a tablet containing 100 mg of bedaquiline fumarate, or (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol, fumarate salt, together with the active ingredient bedaquiline. The fumarate salt can be prepared by reacting the corresponding bedaquiline free base with fumaric acid in the presence of a suitable solvent, such as isopropanol. In the adult population, the initial approval in Europe is for the use of Sirturo® as part of a combination regimen for pulmonary MDR-TB under certain conditions (when an effective treatment regimen cannot be constructed otherwise due to resistance or tolerability reasons). It has been indicated that Sirturo® should be used in combination with at least three other medicines to which the patient's isolate has been shown to be susceptible in vitro. If in vitro test results are unavailable, treatment may be initiated with Sirturo® in combination with at least four medications to which the patient's isolate is likely to be susceptible. The product may also be administered by directly observed therapy (DOT). The recommended dosage is: (i) Weeks 1-2: 400 mg (four 100 mg tablets) once daily, and (ii) Weeks 3-24: 200 mg (two 100 mg tablets) three times weekly (at least 48 hours between doses). The total duration of treatment with Sirturo® is 24 weeks. The other medications used in combination may or should be continued after treatment with Sirturo® is completed.
[0007] Bedaquiline is known to be active against mycobacteria, including drug-resistant strains, particularly M. tuberculosis, M. bovis, M. avium, M. leprae, M. marinum, M. kansasii, and M. abscessus. The active ingredient, including its salts, is active against active, sensitive, and hypersensitive mycobacterial strains as well as latent, dormant, and persistent mycobacterial strains.
[0008] WO 2004 / 011436 discloses the activity of bedaquiline free base against mycobacteria. Later publications such as WO 2005 / 117875 and WO 2006 / 067048 disclose the use of bedaquiline in the treatment of, inter alia, drug-resistant and latent tuberculosis. WO 2008 / 068231 describes the suitability of fumarate as a formulation exhibiting acceptable bioavailability. The fumarate salt of bedaquiline is described as non-hygroscopic and stable. This publication also discloses the preparation of specific formulations and tablets containing bedaquiline fumarate.
[0009] Given bedaquiline's activity against nontuberculous mycobacteria (particularly Mycobacterium abscessus and Mycobacterium avium), there have been reports of off-label use of bedaquiline, as described in Philley et al., Chest 2015, 148(2), 499-506. This paper notes that bedaquiline has not undergone clinical trials for its efficacy in NTM-mediated disease. It describes a small study of patients treated for 1 to 8 years, who were already on treatment at the time of initiation of bedaquiline therapy, and 80% had macrolide-resistant isolates. Bedaquiline was administered according to the dose used in the TB study; in these studies, patients also received companion medications (an average of five total medications). The journal article states, "Further studies are clearly needed to determine whether bedaquiline plays a role in the management of NTM lung disease and, if so, to guide its appropriate use." WO 2020 / 144197 describes certain drug combinations for the treatment of diseases associated with NTM.
[0010] A summary and specific bedaquiline clinical results were presented at the "Advances in the Management of Pulmonary NTM Disease" conference in San Diego in May 2018, where the topic was "Macrolide-Resistant Mycobacterium Avium Complex Lung Disease Treated with Bedaquiline." It described patients with macrolide-resistant MAC lung disease receiving bedaquiline according to package guidelines in combination with a companion drug given at the discretion of two NTM pulmonary physicians. It noted that "treatment options for macrolide-resistant MAC lung disease remain limited" and that "bedaquiline used with companion therapy may be an option for drug-resistant disease." Summary of the Invention [Means for solving the problem]
[0011] As described herein, there is currently a need for effective treatments for NTM-associated diseases. Provided herein are novel combinations for clinical use in the treatment of NTM-associated diseases, as well as novel methods of treating NTM-associated diseases. [Brief explanation of the drawings]
[0012] [Figure 1] Mean concentration-time profiles of bedaquiline and M2. [Figure 2] Mean concentration-time profiles of clarithromycin and 14-OH-clarithromycin. [Figure 3] Simulated mean plasma bedaquiline trough concentrations in standard and alternative regimens based on an updated population pharmacokinetic model. DETAILED DESCRIPTION OF THE INVENTION
[0013] The present disclosure provides a drug component combination comprising (e.g., consisting of) a first drug component that is bedaquiline, a second drug component that is a macrolide (e.g., clarithromycin or azithromycin), and optionally a third drug component having activity against NTM, such as ethambutol, for use in treating diseases associated with nontuberculous mycobacteria (NTM) in a specific treatment regimen. In one embodiment, the first, second, and optional third drug components are the only drug components in the combination. In one embodiment, the aforementioned combination comprises (e.g., consisting of) a first drug component that is bedaquiline and a second drug component that is a macrolide (e.g., clarithromycin or azithromycin). In one embodiment, the first and second drug components are the only drug components in the combination. In one embodiment, the aforementioned combination comprises (e.g., consists of) a first drug component that is bedaquiline, a second drug component that is a macrolide (e.g., clarithromycin or azithromycin), and a third drug component that is ethambutol. In one embodiment, bedaquiline is administered in the form of bedaquiline or a salt thereof. In one embodiment, bedaquiline is administered in the form of bedaquiline fumarate. In one embodiment, the macrolide is clarithromycin. In one embodiment, clarithromycin is administered in the form of clarithromycin or a salt thereof. In one embodiment, clarithromycin is administered in the form of clarithromycin. In one embodiment, the macrolide is azithromycin. In one embodiment, azithromycin is administered in the form of azithromycin or a salt thereof. In one embodiment, azithromycin is administered in the form of azithromycin dihydrate. In one embodiment, the third drug component is ethambutol. In one embodiment, ethambutol is administered in the form of ethambutol or a salt thereof, or in the form of ethambutol hydrochloride.
[0014] In one embodiment, there is provided a method of treating a disease associated with NTM in a patient in need thereof, comprising administering to the patient: (i) a first drug component that is bedaquiline; and (ii) a second drug component that is a macrolide (e.g., clarithromycin or azithromycin); and (iii) optionally, a third drug component that is ethambutol, Methods are provided that include administering in a specific therapeutic regimen.
[0015] In one embodiment, the combination comprises (e.g., consists of) a first and a second drug component. In one embodiment, the first and second drug components are the only drug components in the combination. In one embodiment, the combination comprises (e.g., consists of) a first, second, and third drug component. In one embodiment, the first, second, and third drug components are the only drug components in the combination.
[0016] In one embodiment, bedaquiline is administered in the form of bedaquiline or a salt thereof. In one embodiment, bedaquiline is administered in the form of bedaquiline fumarate. In one embodiment, the macrolide is clarithromycin. In one embodiment, clarithromycin is administered in the form of clarithromycin or a salt thereof. In one embodiment, clarithromycin is administered in the form of clarithromycin. In one embodiment, the macrolide is azithromycin. In one embodiment, azithromycin is administered in the form of azithromycin or a salt thereof. In one embodiment, azithromycin is administered in the form of azithromycin dihydrate. In one embodiment, the third drug component is ethambutol. In one embodiment, ethambutol is administered in the form of ethambutol or a salt thereof, or in the form of ethambutol hydrochloride. In one embodiment, the first, second, and third drug components are the only drug components in the combination.
[0017] In the embodiments referred to herein, the combination of the present invention is used in a specific treatment or administration regimen.For example, the method of treating a disease (related to NTM) in a patient disclosed herein can have a specific treatment or administration regimen.Such a treatment or administration regimen can include or consist of: (i) Bedaquiline: Weeks 1-2: 400 mg once daily (or "qd"), Weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48): 200 mg twice weekly (e.g., once daily on two different days per week, e.g., at least 48 hours apart, or at least 72 hours apart); (ii) Macrolides: for example, clarithromycin, 800 mg / day, e.g., 400 mg twice a day (i.e., 400 mg "bid"); azithromycin, 250 mg / day; (iii) Ethambutol, when used: 5 to 50 mg / kg daily (e.g., 1 to 30 mg / kg daily, e.g., 15 mg / kg daily); but alternatively, the dosage is 500 to 750 mg qd (i.e., daily) or a maximum daily dose of 1 g.
[0018] In one embodiment, such a treatment or administration regimen is safe and effective for treating a disease associated with NTM.
[0019] These combinations referred to herein are referred to herein as "combinations of the present invention." As noted above, combinations of the present invention may include two or three drug components (bedaquiline, a macrolide, and optionally ethambutol). As used herein, a "drug component" is an agent classified as an antibacterial or antibiotic agent and / or active against pathogenic bacteria such as mycobacteria, and in one embodiment, specifically active against nontuberculous mycobacteria (e.g., Mycobacterium avium and Mycobacterium abscessus). In one embodiment, a combination of the present invention contains these two or three drug components as the only drug components. In one embodiment, such a combination also includes another drug component (optionally, a third or fourth drug component) that is an aminoglycoside (e.g., an injectable or inhalable agent). As used herein, a "macrolide" is an antibiotic or antibacterial macrolide pharmaceutical (typically containing a large (e.g., 14-, 15-, or 16-membered macrocyclic lactone attached to one or more deoxy sugars). Examples of macrolides include erythromycin, clarithromycin, roxithromycin, azithromycin, fidaxomicin, spiramycin, and / or troleandomycin). As used herein, an "aminoglycoside" is an antibacterial pharmaceutical agent having an amino-modified glycoside structure and activity against Gram-negative bacteria. The use of an aminoglycoside may be appropriate, for example, in severe cases of mycobacterial infection or for patients who do not respond to first-line oral therapy. In one embodiment, an aminoglycoside is not used, particularly in certain patient populations (e.g., where it is not needed or can be avoided). In one embodiment, the aminoglycoside may be any suitable one already approved by a regulatory agency (e.g., for the treatment of Mycobacterium avium complex pulmonary disease as part of a combination antibacterial regimen), such as a suitable one approved by the U.S. Food and Drug Administration (FDA), such as gentamicin, tobramycin, amikacin, plazomycin, streptomycin, neomycin, and / or paromomycin.In one embodiment, a combination described herein comprises bedaquiline, a macrolide, an aminoglycoside, and optionally ethambutol. In one embodiment, the combination comprises bedaquiline, a macrolide, an aminoglycoside, and optionally ethambutol as the only drug components in the combination. In such an embodiment, the combination (or a method of treatment comprising administering such a combination to a patient) does not comprise any other drug components.
[0020] The combinations of the present invention may include additional drug components (in addition to the two required drug components and optional ethambutol), where "additional drug components" is meant to be one (or more) drug(s) classified as antibacterial or antibiotic agents, thereby including drugs already known or reported to be antibacterial or antibiotic agents, and drugs that can be tested to achieve a particular antibacterial / antibiotic threshold (e.g., in a standard test or assay that measures the lowest concentration (mg / mL) of antibacterial agent that inhibits the growth of a given strain, i.e., measures an MIC value). Thus, an antibacterial or antibiotic agent may be defined as an agent that achieves an MIC of less than 3, e.g., less than 1 or less than 0.5 (although this depends on the actual test employed). More specifically, when a drug is shown herein to have "activity against NTM," it means that it inhibits the growth of nontuberculous mycobacterial strains (e.g., Mycobacterium avium or another known strain) and achieves a particular threshold, e.g., an MIC (or pIC), such as those mentioned herein, in a standard test or assay. 50 / pIC 90 ) value. It will be understood that antibacterial agents or antibiotics may act against bacteria (e.g., mycobacteria) in a bacteriostatic (stopping the growth of bacteria, but not necessarily killing them) or bacteriocidal (killing bacteria) manner. In one embodiment, as noted above, the combination of the present invention does not include such "additional drug components."
[0021] The first, second, and optionally third and optional fourth drug components (e.g., bedaquiline, macrolide, and in one embodiment, ethambutol, and in one embodiment, aminoglycoside) in the combinations of the invention may be formulated separately (e.g., as defined herein), or one or more of the drug components (e.g., bedaquiline and macrolide, bedaquiline and ethambutol, macrolide and ethambutol, or bedaquiline, macrolide and ethambutol) may be formulated together. In one embodiment, such drug components (e.g., bedaquiline, macrolide, and optionally ethambutol and / or aminoglycoside) are formulated separately, e.g., in the form in which they are marketed / commercially available (for existing approved indications) or in the form described herein. In embodiments where such combinations also include additional drug components (e.g., a third or fourth drug component, as appropriate), such as an aminoglycoside (such as injectable or inhalable form), such components are also formulated separately, e.g., in the form in which they are commercially available or as described herein.
[0022] In various embodiments (including methods of treating a disease associated with NTM in a patient), the drug components of the combination of the invention (e.g., bedaquiline, macrolide, optional ethambutol, and optional aminoglycoside) can be administered simultaneously; in other embodiments, the drug components of the combination can be administered sequentially; and in still other embodiments, they can be administered substantially simultaneously. In some of the latter embodiments, administration involves taking such drug components (e.g., bedaquiline, macrolide, optional ethambutol, and optional aminoglycoside) within 30 minutes of each other, and in some embodiments within 15 minutes of each other. In some embodiments, the drug components (e.g., bedaquiline, macrolide, optional ethambutol, and optional aminoglycoside) are administered at least once daily (in this case, either as a single daily dose or as one of two daily doses, i.e., when such drug components are administered twice daily) at approximately the same time each day. For example, the different drug components are administered within 4 hours of each other on a given administration day, or within 2 hours of each other, or within 1 hour of each other, or in still other embodiments, within 30 minutes of each other on a given administration day. However, in one embodiment, the drug components of the combination of the invention (including bedaquiline, a macrolide, and optionally ethambutol, and optionally an aminoglycoside) are administered in accordance with existing guidelines (e.g., in accordance with the regulatory labeling for the indication(s) for which the relevant active agents are approved).
[0023] In some embodiments, the first, second, and optional third drug components of the combination of the present invention are administered as separate oral dosage forms, such as oral capsules or oral tablets. Other formulations may include solid dispersions. In some embodiments, the aminoglycoside is administered as an injection (e.g., subcutaneously or intravenously) and / or as an inhalable (e.g., as a powder, suspension, or liposomal suspension).
[0024] The drug components described herein can be used in free drug form or as their pharmaceutically acceptable salts or co-crystals. The drug components (including free forms and salts or co-crystal forms) can be used in solvate forms with suitable solvents, including water (e.g., hydrate forms or alcoholates, particularly hydrate forms such as hydrates, hemihydrates, monohydrates, or dihydrates). Bedaquiline, clarithromycin, azithromycin, and ethambutol can be used in free base form or in suitable pharmaceutically acceptable salt forms (e.g., acid addition salt forms). In one embodiment, bedaquiline is administered in the form of bedaquiline or a salt thereof, such as bedaquiline fumarate. In one embodiment, clarithromycin is administered in the form of clarithromycin. In one embodiment, azithromycin can be used in the form of azithromycin or a salt thereof. Azithromycin includes azithromycin or hydrate forms of azithromycin, such as the monohydrate or dihydrate. In one embodiment, azithromycin is administered as azithromycin dihydrate. In one embodiment, ethambutol is administered in the form of ethambutol or a salt thereof, or in the form of ethambutol hydrochloride.
[0025] Pharmaceutically acceptable acid addition salts are defined to include therapeutically effective, non-toxic acid addition salt forms that bedaquiline, azithromycin, clarithromycin, or ethambutol can form. These acid addition salts can be obtained by treating the free form of the drug substance with a suitable acid, such as inorganic acids, such as hydrohalic acids, particularly hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, or organic acids, such as acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicylic acid, p-aminosalicylic acid, and pamoic acid. Conversely, acid addition salt forms can be converted to the free form by treatment with a suitable base. In particular, the fumarate salt is considered to be bedaquiline, given that this is the form used in the commercially available product Sirturo®. The fumarate salt of bedaquiline can be prepared by reacting the corresponding free base with fumaric acid in the presence of a suitable solvent, such as isopropanol. In particular, the hydrochloride salt is considered for ethambutol, since this is the commercially available form. In one embodiment, the macrolide (e.g., clarithromycin or erythromycin) and ethambutol can be administered in the form that is commercially available or approved for sale by the health authorities.
[0026] For the drug components discussed herein, each drug component may be used in a single stereoisomeric form or, where applicable, as a mixture of stereoisomers. Whenever reference is made to bedaquiline herein, we refer to the single stereoisomeric form used in the marketed product Sirturo® and disclosed in WO 2004 / 011436 as an antimycobacterial agent.
[0027] For example, bedaquiline can be formulated, e.g., as the fumarate salt, and administered as a tablet containing 100 mg of the active ingredient bedaquiline. If the macrolide used is clarithromycin, it can be administered as a 500 mg tablet (or as an available suspension containing, e.g., 250 mg / 5 mL, depending on the required dose and patient). Ethambutol can be administered as ethambutol hydrochloride in tablets with 100 mg or 400 mg of ethambutol active ingredient (depending on the required dose).
[0028] For example, the dosing regimens referred to herein are applicable to diseases associated with NTM as defined / described below, and particularly to NTM-PD. The severity or type of disease or the severity of mycobacterial infection may also determine the dose or dosing regimen. In one embodiment, the American Thoracic Society (ATS) guidelines for dosing macrolides (e.g., clarithromycin) and ethambutol for certain diseases associated with NTM may be followed.
[0029] The overall treatment regimen may last at least 24 weeks, e.g., at least 32 weeks, e.g., about 48 weeks or about 52 weeks (however, in one embodiment, the treatment period may last up to 18 months or even 24 months). In this regard, the bedaquiline dosing regimen has already been described above for a possible duration of 52 weeks (if the duration extends to 18 or 24 months, the dosing regimen lasts 3 to 48 weeks (or 3 to 52 weeks)); similarly, the administration of the macrolide (e.g., clarithromycin or azithromycin) and optionally ethambutol lasts for a relevant period, e.g., at least 24 weeks, at least 32 weeks, e.g., about 48 weeks or about 52 weeks (or in another embodiment, up to 18 months or up to 24 months). In one embodiment, the treatment regimen also includes an aminoglycoside, e.g., in injectable or inhalable form (e.g., in situations where the ATS guidelines recommend, e.g., when the disease is severe, in which case, e.g., three injections per week may be administered). In one embodiment, the treatment regimen does not include other drug components. However, for example, a companion drug for treating another disease (e.g., may already be administered to the patient) may be acceptable (especially if such a drug is for a disease other than bacterial infection and, for example, its drug-drug interaction with one or more of the drug components of the combination of the present invention has already been studied), but in one embodiment, any other drug is not administered during the treatment regimen described herein.
[0030] In one embodiment the macrolide used in the combination of the present invention is clarithromycin.In one embodiment the macrolide used in the combination of the present invention is azithromycin.
[0031] In one embodiment, bedaquiline is administered postprandially (e.g., immediately after a meal or with food), as this may increase the bioavailability of the drug.
[0032] In one embodiment, administration of the macrolide (eg, clarithromycin or azithromycin) and optionally ethambutol is in accordance with local guidelines.
[0033] In one embodiment, the first, second, and optionally third drug components of the combination of the invention are administered orally, with administration occurring at about the same time each day (or, if the drug components are administered twice daily, such administration refers to one of the twice-daily doses).
[0034] All dosage amounts referred to in this disclosure refer to free base equivalents (i.e., amounts calculated relative to the free base form of a particular drug component). The values given below represent free form equivalents, i.e., amounts as if the free form were administered. When a salt is administered, the amount must be calculated as a function of the molecular weight ratio between the salt and the free form.
[0035] The daily doses given herein are calculated for an average body weight of about 70 kg and must be recalculated for pediatric applications or when used in patients of substantially different body weights.
[0036] The combinations used herein are herein shown to be useful for the treatment of diseases associated with nontuberculous mycobacteria (NTM). A method of treatment is also described herein, which relates to the treatment of diseases associated with NTM in a patient in need thereof, wherein the patient is administered an effective amount of a combination of the present invention.
[0037] As used herein, the term "NTM-associated disease in a patient" refers to a patient (or subject, e.g., a human patient) infected with nontuberculous mycobacteria (particularly Mycobacterium abscessus and Mycobacterium avium). In particular, such a disease can be a pulmonary disease caused by NTM, and thus, in one embodiment, the disease is NTM-PD. NTM-PD differs from the pulmonary infection caused by Mycobacterium tuberculosis, for which bedaquiline is currently indicated. Mycobacterium avium is one of several species within the MAC family, accounting for up to 70% of NTM-positive sputum cultures (although this varies geographically). MAC species are common, naturally occurring organisms in water and soil that often colonize natural water sources such as indoor water systems, hot tubs, and swimming pools. MAC-PD is most frequently seen in postmenopausal women and patients with underlying lung disease (such as cystic fibrosis or bronchiectasis) or immunodeficiency. Clinical symptoms vary in scope and intensity but commonly include a chronic cough, often accompanied by purulent sputum, although hemoptysis may also be present. Systemic symptoms include malaise, fatigue, and, in advanced disease, weight loss.
[0038] Included in the NTM-PD population are treatment-refractory NTM-PD patients, and as noted above, the most common form of NTM-PD is MAC-PD. Thus, in one embodiment, when the term "NTM-associated disease" is referred to herein, it generally refers to NTM-PD, and in a further embodiment, it refers to NTM-PD in treatment-refractory patients. In a further embodiment, it refers to MAC-PD, and in yet a further embodiment, it refers to MAC-PD in treatment-refractory patients. Treatment-refractory MAC-PD patients are defined as those with a positive sputum culture for MAC after at least six months of guideline-based treatment for MAC-PD infection. Refractory patients treated with current standard of care have very poor clinical outcomes, with an eventual culture conversion rate of approximately 10% after 12 months of treatment, even with intensification of treatment and the use of aminoglycosides. Thus, this patient population also represents an area of unmet medical need. In one embodiment, an NTM-associated disease (e.g., NTM-PD, such as MAC-PD) is associated with an underlying lung disease (e.g., cystic fibrosis or another disease mentioned herein). In one embodiment, the disease associated with NTM is NTM-PD, MAC-PD, fibrocavitary NTM-PD, or treatment-refractory NTM-PD. In one embodiment, diseases associated with NTM (e.g., NTM-PD such as MAC-PD) do not include fibrocavitary NTM-PD. In one embodiment, diseases associated with NTM (e.g., NTM-PD such as MAC-PD) do not include patients with cystic fibrosis. In one embodiment, the patient in need of a treatment described herein is also diagnosed with bronchiectasis, COPD, asthma, or cystic fibrosis.
[0039] Due to its unique mode of action (inhibition of ATP synthase), bedaquiline represents a new class of anti-NTM compound, with no other drugs currently available belonging to the same pharmacological class, thus minimizing the possibility of cross-resistance. The combinations of the invention described herein therefore have the advantage of having bedaquiline as a component thereof.
[0040] As used herein, "effective amount" refers to the amount of each component of the combination of the present invention, or any pharmaceutically acceptable salt thereof, that elicits the biological or medical response in a tissue system (e.g., blood, plasma, biopsy) or warm-blooded animal (e.g., human) that is desired by a health care provider, including alleviation of the symptoms of the disease being treated.
[0041] A patient treated according to the methods of the present disclosure may be a "first-line" patient. As used herein, this refers to a patient who has not previously received treatment with any drug (investigational or approved) for the disease (related to NTM) to be treated. In a further embodiment, the patient being treated is not a first-line patient, but a patient who has already been treated, e.g., a patient diagnosed with the disease who still tests positive after 6 months of other guideline therapy (i.e., tests positive in sputum culture for MAC after at least 6 months of guideline-based therapy). Thus, in one embodiment, the patient is a treatment-refractory or salvage patient. In a further embodiment, the NTM isolate is not macrolide-resistant.
[0042] To date, no surrogate markers predictive of clinical treatment response have been defined. The current primary endpoint for "treatment" is sputum culture conversion, defined as three consecutive monthly negative sputum cultures up to six months after the start of treatment. For example, the primary efficacy outcome time point was chosen at six months because the majority of bacterial responses occurred during this period in the recently completed ALIS trial, as described, for example, in Griffith et al., Am.J.Crit.Care Med. 2017, 195(6), 814-823, and Griffith et al., Am.J.Crit.Care Med. 2018, 198(12), 1559-1569.
[0043] As noted herein, the combinations of drug components described herein may be administered simultaneously, sequentially, or substantially simultaneously (as described herein). Thus, individual dosage forms of each of the drug components may be administered in separate forms (e.g., as separate tablets or capsules) as described herein.
[0044] In one embodiment there is provided a process for preparing a combination product as defined herein, comprising: - associating each of the components of the combination product (e.g., as separate pharmaceutical formulations), co-packaging (e.g., as a kit of parts), or indicating that the intended use is in combination (with other components); and / or - associating each of the ingredients in preparing a pharmaceutical formulation comprising the ingredients.
[0045] In current MAC-PD regimens in which rifamycin is combined with clarithromycin, exposure to clarithromycin has been reported to be suboptimal due to metabolic induction by the rifamycin component, as described, for example, in Shimomura et al., J. Pharm. Health Care Sci. 2015, 1, 32. The combination of the present invention may overcome this. The combination of the present invention may also have the advantage of being more effective, having a better safety profile, and / or having fewer side effects than existing or recommended treatment regimens (e.g., those recommended by the ATS). In one embodiment, the combination of the present invention has better efficacy or a lower incidence and / or risk of certain side effects (e.g., death, QT prolongation, nausea, arthralgia, headache, hemoptysis, chest pain, elevated serum transaminase levels, elevated blood amylase levels, anorexia, and rash) than a comparative combination including three doses of bedaquiline per week in Phase 2 (week 3 and beyond). In one embodiment, the combination of the present invention has better efficacy or a lower incidence and / or lower risk of certain side effects associated with rifamycin use, including "flu syndrome" (fever, chills, fatigue), hematopoietic reactions (leukopenia, thrombocytopenia, or acute hemolytic anemia), shortness of breath, shock, anaphylaxis, and renal failure, than a comparative combination with a rifamycin. In one embodiment, the combination of the present invention provides bedaquiline plasma levels within the safety limits already established for bedaquiline, and may therefore reduce the incidence of side effects.
[0046] The following examples are illustrative only and are not intended to limit the disclosure to the materials, conditions, or process parameters described therein. [Example]
[0047] Reference Example 1. In vitro activity of bedaquiline Bedaquiline has a unique spectrum of specificity against mycobacteria, including atypical species important in humans, such as Mycobacterium avium and Mycobacterium kansasii, as well as the fast-growing Mycobacterium fortuitum and Mycobacterium abscessus, which can cause NTM disease.
[0048] The minimum inhibitory concentrations (MICs) of bedaquiline for Mycobacterium tuberculosis ranged from 0.008 μg / ml to 0.12 μg / ml, regardless of resistance subtype. The MICs of bedaquiline were generally less than 0.1 μg / ml for other mycobacterial species, including those naturally resistant to many other anti-TB agents and involved in opportunistic infections such as Mycobacterium avium, Mycobacterium abscessus, Mycobacterium fortuitum, and Mycobacterium marinum. Compared to Mycobacterium tuberculosis, higher MICs were found for one isolate each of Mycobacterium abscessus (0.25 μg / ml) and Mycobacterium ulcerans (0.50 μg / ml) (see table below). The activity of bedaquiline appeared to be specific for Mycobacterium species (see Andries et al. Science, 2005, 37, 223-227).
[0049] [Table 1]
[0050] Example 2: Drug-drug interaction studies Reference is made herein to the measurement of bedaquiline and its known active metabolite (M2, a methyl-substituted metabolite formed as a result of N-demethylation of the dimethyl-substituted amino group).
[0051] summary method: This phase 1 randomized crossover study evaluated the effect of steady-state clarithromycin (500 mg BID (every 12 hours) for 14 days) on the pharmacokinetic (PK) parameters of bedaquiline and its metabolite (M2) after a single dose of bedaquiline (100 mg; n=16).
[0052] Summary of results: Maximum plasma concentration of bedaquiline (C max ) and C max No effect on the time to achieve M2 was observed, but the mean plasma exposure of bedaquiline after a single dose on day 5 increased by 14% after 10 days of clarithromycin coadministration, accompanied by slower formation of M2.
[0053] Simulation Test Using these PK data, population pharmacokinetic modeling and simulations were performed to determine the effect of clarithromycin (under steady-state conditions) on bedaquiline exposure. Furthermore, simulations demonstrated that coadministration with clarithromycin (under steady-state conditions) resulted in higher bedaquiline plasma trough concentrations (up to 41% by week 48) compared with monotherapy (400 mg once daily [qd] for 2 weeks, followed by 200 mg three times weekly for 46 weeks, referred to herein as the reference regimen). Overall exposure for the simulated bedaquiline regimen (400 mg qd for 2 weeks, followed by 200 mg twice weekly [biw] for 46 weeks) with clarithromycin (under steady-state conditions) was comparable to monotherapy (less than 15% difference).
[0054] conclusion Based on these results, the combination of bedaquiline (400 mg qd for 2 weeks followed by 200 mg biw for 46 weeks, i.e., twice weekly for 46 weeks) with clarithromycin (under steady-state conditions) was selected as the regimen to be investigated for efficacy and safety in NTM lung disease (NTM-PD, e.g., MAC-PD).
[0055] Advantageously, during the second phase of treatment, based on the results of drug-drug interaction (and simulation) studies, the bedaquiline dose could be reduced from three times per week to twice per week, ensuring that bedaquiline plasma levels remained within established safety limits and thus avoiding potential side effects.
[0056] Detailed methods and results method Body mass index (BMI) of 18.0 to 30.0 kg / m at screening 2 Healthy adults aged 18 to 55 years (including extremes) with a body weight of 50 kg or greater were included. This was a phase 1, single-center, two-series, open-label, randomized, two-way crossover study conducted in healthy adults to evaluate the drug-drug interaction between single-dose bedaquiline and clarithromycin under steady-state conditions.
[0057] Subjects were assigned to the following treatment groups based on a computer-generated randomization schedule: Treatment A: A single oral dose of 100 mg bedaquiline (1 × 100 mg commercially available tablet formulation, SIRTURO® [Janssen Pharmaceutica NV, Beerse, Belgium]) will be taken with a standardized breakfast on the morning of Day 1. Treatment B: From days 1 to 14, an oral dose of 500 mg clarithromycin (1 x 500 mg film-coated commercially available tablet formulation, CLARITHROMYCIN SANDOZ® (Sandoz NV, Vilvoorde, Belgium)) will be taken every 12 hours (q12h) at the study site on days 1 and 2, and on the mornings of days 4-8 with a standardized breakfast (other self-administration at home may be with or without meals), and a single oral dose of 100 mg bedaquiline (1 x 100 mg commercially available tablet, SIRTURO®) will be taken with a standardized breakfast on the morning of day 5.
[0058] Each subject received both treatments consecutively in either the AB or BA order, with a washout period of at least 28 days between treatments. The study duration for each subject was at least 62 days, excluding the screening period.
[0059] Pharmacokinetic evaluation For determination of bedaquiline and M2 plasma concentrations, blood samples were collected from 2 hours before administration of bedaquiline until 240 hours after administration of bedaquiline in Treatments A and B. For determination of clarithromycin and 14-OH-clarithromycin plasma concentrations, blood samples were collected 30 minutes before administration of bedaquiline and clarithromycin until 12 hours after administration on Day 5 of Treatment B (1, 2, 3, 4, 5, 6, 8, and 12 hours after administration).
[0060] Based on the individual plasma concentration-time data, the following PK parameters were determined for bedaquiline and M2 on Day 1 of Treatment A and Day 5 of Treatment B: maximum observed analyte concentration (C max ), C max The actual sampling time (t max ), area under the analyte concentration-time curve (AUC) from 0 to 72 hours (AUC 72h ), and AUC from 0 to 240 hours (AUC 240h ). C max , t max , minimum observed analyte concentration (C min ), and AUC from 0 to 12 hours (AUC 12h ) PK parameters were calculated for clarithromycin and 14-OH-clarithromycin on Day 5 of Treatment B. Metabolite-to-parent (M / P, M2 / bedaquiline [BDQ]) ratios for the following PK parameters were also determined: max、M2 / BDQ , AUC 72h、M2 / BDQ , and AUC 240h、M2 / BDQ .
[0061] Bioanalytical methods: Plasma samples were analyzed to determine concentrations of bedaquiline, M2, clarithromycin, and 14-OH-clarithromycin using validated liquid chromatography-mass spectrometry / mass spectrometry assays at the sponsor's bioanalytical laboratories (PRA Health Sciences, The Netherlands for bedaquiline, and PPD, USA for clarithromycin assays). The quantification ranges were 1-2,000 ng / mL for bedaquiline / M2, 20-10,000 ng / mL for clarithromycin, and 5-2,500 ng / mL for 14-OH-clarithromycin.
[0062] Simulation Test Method Population pharmacokinetic (popPK) modeling and simulation were performed using bedaquiline concentration data. The analysis was based on a previously developed popPK model, which was a four-compartment model with a double zero-order output for healthy subjects and tuberculosis patients after bedaquiline monotherapy. The previous model was evaluated for its applicability to data collected from Treatment A (using maximum a posteriori estimation in NONMEM®; visual predictive check [VPC] and goodness-of-fit [GOF] plots were used for model evaluation). The structural and covariate model parameters were then applied to the current data (updated model). Details of the model parameters are listed in the table below (McLeay, SC, Vis, P., van Heeswijk, RP, Green, B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob. Agents. Chemother. 58, 5315-5324 (2014)).
[0063] [Table 2] BSV = intersubject variability, CL / F = apparent clearance, V c / F = apparent central volume of distribution, CL p1-3 / F = apparent intercompartmental clearance, Vp1-3 / F = apparent peripheral volume of distribution, ALAG1 = absorption lag time, TLAG = additional lag time of absorption of the second pathway, KA = absorption rate constant, D1 = entry duration of the first pathway, D2 = entry duration of the second pathway, FR1 = fraction of dose into the depot compartment, RUV = unknown residual variation, CV = coefficient of variation. a Covariates used in simulation of bedaquiline exposure for nontuberculous mycobacterial patients (reference [no effect of clarithromycin on CL / F] and regimens AD). b Covariates considered in the Bayesian posterior estimation of this study. c McLeay SC et al, 2014
[0064] The effect of clarithromycin on the apparent clearance (CL / F) of bedaquiline was then estimated using the combined PK data from Treatments A and B. First-order conditional estimation was used for parameter estimation, with the following equation: CL / F=CL pop (1+θ) CLRi In the formula, CLR i is the clarithromycin coadministration status value (no coadministration = 0 or coadministration = 1), and CL pop is the population central tendency for CL / F without concomitant clarithromycin administration, and θ is the change in apparent bedaquiline clearance with concomitant clarithromycin administration.
[0065] The updated model was then used to simulate bedaquiline PK profiles to assess the impact of clarithromycin coadministration (under steady-state conditions) on bedaquiline exposure in 1,000 non-black subjects (male:female ratio 1:1) and assuming similar disease states for MDR-TB and NTM. Similar bedaquiline exposure levels achieved by the MDR-TB regimen (duration: 24 weeks) were targeted for NTM treatment (duration: 48 weeks), but with clarithromycin coadministration. Plasma bedaquiline trough concentrations (C) of a standard MDR-TB dosing regimen with a longer treatment duration (i.e., 400 mg bedaquiline once daily [qd] for 2 weeks, followed by 200 mg three times weekly [tiw] for 46 weeks) were also assessed. trough ) profiles were simulated with and without concomitant clarithromycin administration (500 mg q12h for 48 weeks as standard NTM treatment). The MDR-TB regimen (without clarithromycin) was selected as the reference regimen based on similar minimum inhibitory concentrations of bedaquiline against NTM and MDR-TB shown in a previous study (Huitric, E., Verhasselt, P., Andries, K., Hoffner, S.E. In vitro antimycobacterial spectrum of a dilquinoline ATP synthase inhibitor. Antimicrob. Agents. Chemother. 2007, 51, 4202-4204).
[0066] The reference regimen (i.e., bedaquiline 400 mg once daily [qd] for 2 weeks, followed by 200 mg three times weekly for 46 weeks, reference regimen) was compared with the following four bedaquiline regimens (with clarithromycin): regimen A (400 mg qd for 2 weeks, followed by 200 mg twice weekly [biw] for 46 weeks), regimen B (400 mg qd for 2 weeks, followed by 100 mg tiw for 46 weeks), regimen C (400 mg qd for 2 weeks, followed by 100 mg biw for 46 weeks), and regimen D (400 mg qd for 2 weeks, followed by 100 mg five times weekly for 46 weeks).
[0067] Population-specific pharmacokinetic (POP) analyses were performed using NONMEM 7.3 (ICON plc, Hanover, MD, USA) with Perl-speaks-NONMEM (PsN, version 4.2.0). The statistical software R (version 3.4.1) was used for data management, exploratory analysis, diagnostic graphics, data post-processing, and NONMEM output.
[0068] result This study enrolled 16 subjects and was conducted at a single site in Belgium from March 2019 to June 2019. These 16 subjects (9 women and 7 men) were Caucasian, with a median age of 43.0 years (range: 24-55 years) and a median BMI of 22.44 kg / m 2 (Range: 18.9-29.5 kg / m 2 ) of all patients. Four patients missed one or more clarithromycin doses. One of these was reported as a major protocol deviation. The subject missed three clarithromycin doses: the evening dose on Day 13 and the morning and evening doses on Day 14. No impact on PK samples was anticipated, so no action was taken.
[0069] Pharmacokinetic findings - bedaquiline and M2 In all subjects, pre-dose plasma concentrations of bedaquiline and M2 in Period 2 were determined after administration of a single dose of bedaquiline in Sequence AB (bedaquiline monotherapy) and Sequence BA (coadministration with clarithromycin) in Period 1. Therefore, the plasma concentrations of bedaquiline and M2 before a single dose of bedaquiline in Period 2 were determined based on the C obtained after a single dose of bedaquiline in Period 2. max less than 5% and more than 10% of the results, respectively.
[0070] Mean bedaquiline plasma concentrations were highest at 5 hours post-dose in both treatment groups, then declined rapidly at first, then more slowly, and remained quantifiable up to 240 hours post-dose. Mean M2 plasma concentrations peaked at 12 hours post-dose in both treatment groups and then declined slowly (a slight re-increase was observed after Treatment B before plasma concentrations gradually declined). M2 formed slowly but remained quantifiable up to 240 hours. Overall, bedaquiline plasma concentrations were slightly higher and M2 levels lower when coadministered with clarithromycin compared with monotherapy (Error! Reference source not found).
[0071] The PK parameters of bedaquiline and M2, as well as a summary of the statistical analysis, are shown in the following tables, respectively. max and C max was similar in both treatment groups, but the mean AUC was slightly higher in Treatment B compared to Treatment A. 72h (5% to 6% higher) and AUC 240h Higher values were observed in period 2 compared to period 1 for both (8%-18% higher). M2 formed more slowly in treatment B (median t for treatment B). max 23.91 hours vs. 12.00 hours for Treatment A), C max and AUC (including their M / P ratios) were significantly decreased. All M2 PK parameters were higher in Period 2 compared to Period 1 (C in Treatment A). max , AUC 72h , and AUC 240h (36%, 41%, and 46% higher for treatment B, and 2.2-fold, 2.1-fold, and 2.1-fold higher for treatment C, respectively).
[0072] [Table 3] AUC 72h = Area under the analyte concentration-time curve from 0 to 72 hours, AUC 240h = area under the analyte concentration-time curve from 0 to 240 hours, C max = maximum observed serum concentration, C min= minimum observed analyte concentration, M / P = metabolite / parent ratio, M / P ratio AUC 72h = AUC of M2 72h AUC of bedaquiline 72h Divided by, M / P ratio AUC 240h = AUC of M2 240h AUC of bedaquiline 240h Divided by the M / P ratio C max =M2C max C of bedaquiline max Divided by, n = number of subjects, SD = standard deviation, t max = Actual sampling time to reach maximum observed analyte concentration. * t max are shown as median (range). # M / P ratio corrected for molecular weight (bedaquiline: 555.50 g / mol and M2: 541.47 g / mol). Treatment A: a single dose of 100 mg bedaquiline on day 1; Treatment B: clarithromycin 500 mg every 12 hours for 14 days (days 1–14) followed by a single dose of 100 mg bedaquiline on day 5.
[0073] Overall, clarithromycin, when coadministered with bedaquiline, appears to have a significant effect on bedaquiline absorption. max and C max had no effect on AUC 240h increased AUC (AUC 72h 12% [p=0.0011] and AUC 240h 14% [p=0.0002]). max , AUC 72h , and AUC 240h 52%, 51%, and 42% for M / P(C max , AUC 72h , and AUC 240h The PK parameters were significantly reduced (52%, 56%, and 49%) with a significant duration effect for all PK parameters (p<0.0001).
[0074] Clarithromycin and 14-OH-clarithromycin Mean plasma concentration-time profiles for clarithromycin and 14-OH-clarithromycin are presented. Error! Reference source not found. On the morning of Day 5, mean pre-dose plasma concentrations of clarithromycin and 14-OH-clarithromycin were 1,281 ng / mL and 797 ng / mL, respectively. Concentrations peaked 3 hours post-dose and then gradually decreased until 12 hours post-dose (i.e., evening dose), indicating steady state was achieved. Mean C max and C min were 2,972 ng / mL and 976 ng / mL for clarithromycin and 1,152 ng / mL and 636 ng / mL for 14-OH-clarithromycin, respectively. Detailed PK results for clarithromycin and 14-OH-clarithromycin 5 days after clarithromycin administration are shown in the table below.
[0075] [Table 4] AUC 12h = area under the analyte concentration-time curve from 0 to 12 hours, C max = maximum observed serum concentration, C min = minimum observed analyte concentration, n = number of subjects, SD = standard deviation, t max = Actual sampling time to reach maximum observed analyte concentration. * t max are shown as median (range).
[0076] Modeling Results Simulation of steady-state bedaquiline pharmacokinetics Simulated plasma bedaquiline C with coadministration of clarithromycin in MDR-TB regimens based on an updated model trough was found to be higher at 24 weeks (33%, i.e., 1154±576 ng / mL vs. 869±481 ng / mL) and 48 weeks (41%, i.e., 1542±832 ng / mL vs. 1095±661 ng / mL) compared to monotherapy.
[0077] The reference regimen was then compared with four regimens of bedaquiline with clarithromycin. Regimen B and C had lower mean plasma bedaquiline C. trough The profiles were (21% and 46%, respectively) trough Profiles were comparable for regimens A and D compared with the reference regimen (less than 14% difference) (Figure 3). C at weeks 2, 24, and 48 max , AUC 24h , and AUC 168h When comparing regimens A and D with the reference regimen, their exposure profiles were as follows: C at week 24 in regimen D max were similar (less than 15% difference) except for Regimen D, which had a difference of more than 20%.
[0078] [Table 5] AUC = area under the plasma concentration-time curve, C max = maximum observed serum concentration, C trough = trough concentration, SD = standard deviation, wk = week. * Average exposure in regimen A or D / average exposure in MDR-TB regimens. # AUC for week 2 24h , AUC at 24 and 48 weeks 168h . MDR-TB regimen: 400 mg bedaquiline once daily for 2 weeks, followed by 200 mg three times weekly (without clarithromycin); Regimen A: 400 mg once daily for 2 weeks, followed by 200 mg twice weekly for 46 weeks, with clarithromycin Regimen D: 400 mg once daily for 2 weeks, followed by 100 mg five times weekly for 46 weeks, with clarithromycin.
[0079] Consideration Because bedaquiline is currently being considered for clinical trials for non-steroidal anti-metastatic (NTM), this was a first-in-human study evaluating the PK interaction between bedaquiline and clarithromycin to select appropriate dosing / administration regimens for future studies (e.g., phase 2 / 3 clinical trials) and treatment. Bedaquiline is a CYP3A4 substrate, and clarithromycin can act as a CYP3A4 inhibitor. Therefore, this study was necessary to identify specific bedaquiline doses for both the loading and maintenance phases. For example, if clarithromycin increases bedaquiline exposure, this study would be beneficial for selecting the bedaquiline dose and schedule for both treatment phases (loading and maintenance). In this way, this study envisions a safe and effective dosing / administration regimen for the treatment of diseases associated with NTM, such as pulmonary MAC infection (MAC-PD).
[0080] Following administration of bedaquiline alone or with clarithromycin in Period 1, plasma concentrations of bedaquiline and M2 were assessed in Period 2 before bedaquiline administration for all subjects (C associated with the second single dose for bedaquiline and M2, respectively). max Plasma concentrations of bedaquiline and M2 were quantifiable up to 240 hours after bedaquiline administration in both treatments, with a carryover effect observed in Period 2 (bedaquiline: higher AUC 72h and AUC 240h ;M2: higher C max , AUC 72h , and AUC 240hThis was due to the relatively short washout period between both treatment periods compared to the very long terminal elimination half-life of bedaquiline (5.5 months), which is due to its cationic amphiphilic properties (van Heeswijk, RP, Dannemann, B., Hoetelmans, RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J. Antimicrob. Chemother. 2014, 69, 2310-2318). The results are consistent with a previous randomized trial of an 8-week bedaquiline regimen in MDR-TB patients, in which bedaquiline and M2 were quantifiable even 96 weeks after the end of treatment, with mean terminal elimination half-lives of 164 and 159 days, respectively (Diacon, AH, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents. Chemother. 2012, 56, 3271-3276). エラー!参照ソースが見つかりません。 Bedaquiline reaches its maximum concentration within 5 hours after administration, which is consistent with the C max This is consistent with previous studies that reached
[0081] Bedaquiline C max and t max was not affected by concomitant clarithromycin administration, but the mean plasma concentrations of bedaquiline were slightly higher (C for M2 and M / P ratio). max(with a decrease in AUC and CYP3A4 inhibitory activity). Given that clarithromycin potentially acts as a CYP3A4 inhibitor, this increased plasma exposure of bedaquiline, along with a decreased clearance, had to be considered. The mean plasma concentrations of clarithromycin (in combination with bedaquiline) peaked 3 hours after administration and then gradually decreased until 12 hours after administration, when steady state was achieved in the study. The PK profile of clarithromycin has already been well established.
[0082] In summary, coadministration of clarithromycin with a single dose of bedaquiline significantly reduces the C max and t max However, its plasma exposure was increased and that of M2 was decreased. Overall, single-dose bedaquiline also appears to be safe and well tolerated, either alone or in combination with clarithromycin. However, this needs to be evaluated in long-term studies.
[0083] Based on popPK modeling, the effect of clarithromycin on apparent bedaquiline clearance compared with its clearance as monotherapy was estimated to be -37%. Furthermore, the simulated C of bedaquiline with clarithromycin coadministration was trough was found to be higher at weeks 24 and 48 compared with its monotherapy, suggesting that a reduction in bedaquiline dose is warranted, especially in the maintenance period. Based on bedaquiline exposure similar to that of regimens currently used in MDR-TB, the combination of bedaquiline (400 mg qd for 2 weeks followed by 200 mg biw for 46 weeks, Regimen A) and clarithromycin (400 mg bid) was found to be a suitable regimen that can be used in the treatment of NTM-PD (e.g., MAC-PD). The safety and efficacy of this regimen will be confirmed in future studies.
[0084] Considering the above, a combination regimen of bedaquiline with clarithromycin (400 mg qd for 2 weeks followed by 200 mg biw for 46 weeks) was selected for further study for the treatment of NTM-PD (e.g., MAC-PD) disease.
[0085] Example 3: In vivo testing the purpose Main purpose The primary objective was to evaluate the efficacy of bedaquiline compared with rifamycin (rifabutin or rifampin) at 24 weeks when administered as part of a treatment regimen with macrolide (clarithromycin) and ethambutol in adult patients with treatment-refractory MAC-PD.
[0086] Secondary Objectives The secondary objectives are as follows: Microbial evaluation on 7H10 or 7H11 agar: To evaluate the efficacy of BDQ compared with rifamycin when administered as part of a treatment regimen with CAM and EB in adult participants with treatment-refractory MAC-LD at 24 weeks. Clinical evaluation: To evaluate the efficacy of BDQ compared with rifamycin at 24 weeks when administered as part of a treatment regimen with CAM and EB in adult participants with treatment-refractory MAC-LD. Microbiological assessment: To evaluate the efficacy of the study intervention at 48 weeks in adult participants with treatment-refractory MAC-LD. Clinical evaluation: To evaluate the effectiveness of the study intervention in adult participants with treatment-refractory MAC-LD. Microbiological assessment: To evaluate the efficacy of the study intervention at 60 weeks in adult participants with treatment-refractory MAC-LD. To assess the efficacy and tolerability of the study intervention in adult participants with treatment-refractory MAC-LD. To evaluate the PK of BDQ (and metabolite M2) and CAM (and metabolite 4-OH-CAM [optional]).
[0087] endpoint Primary endpoint Percentage of participants with sputum culture conversion (defined as three consecutive negative monthly sputum cultures taken at least 25 days apart) in the MGIT (Mycobacterial Growth Indicator Tube) at week 24 after initiation of study treatment.
[0088] Secondary endpoints Secondary endpoints were: Percentage of participants with sputum culture conversion (defined as three consecutive negative sputum cultures taken at least 25 days apart) on 7H10 or 7H11 agar at week 24. Change from baseline in SGRQ total score on patient-reported health status at week 24. -Percentage of participants with sputum culture conversion (defined as three consecutive negative sputum cultures taken at least 25 days apart) on MGIT and 7H10 or 7H11 agar at week 48; -Percentage of participants with negative sputum cultures on MGIT and 7H10 or 7H11 agar at each visit from week 2 onwards per activity schedule; -Time to sputum culture conversion (defined as three consecutive negative sputum cultures taken at least 25 days apart) on MGIT by week 48; -Time to positivity on MGIT by week 48. Change from baseline in SGRQ total score for patient-reported health status at weeks -48 and 60; change from baseline in lung function parameters at weeks -24, 48, and 60; proportion of participants who underwent a change in MAC-LD treatment regimen by week -24, by week 48 (Arm A), and by week 60 (Arm B). Percentage of participants with sputum culture conversion (defined as three consecutive negative sputum cultures taken at least 25 days apart) on MGIT and 7H10 or 7H11 agar at week 60. Safety and tolerability based on assessment of AEs, clinical laboratory assessments, 12-lead ECG, vital signs, physical examination, visual examination, and audiological examination through Week 60. PK exposure of BDQ (and metabolite M2 [optional]) at days 1, 2, 8, 12, 24, and 48, and CAM and metabolite 4-OH-CAM [optional] at days 1, 2, 8, 12, and 24.
[0089] Test Plan This was a multicenter, randomized, open-label, actively controlled, phase 2a study to evaluate the efficacy of bedaquiline plus macrolide (clarithromycin) and ethambutol versus rifamycin plus macrolide (clarithromycin) and ethambutol in the treatment of adult patients with NTM-PD refractory to MAC therapy.
[0090] Adult participants with MAC-refractory NTM-PD (defined as patients with a positive sputum culture for MAC after at least 6 months of guideline-based treatment) will be enrolled. In one embodiment, subjects with fibrocavitary NTM-PD and cystic fibrosis will be excluded.
[0091] Participants who meet all eligibility criteria will be randomized in a 1:1 ratio to receive one of the following two treatment regimens: Comparison group A: Rifamycin * + Clarithromycin 400 mg twice daily + Ethambutol 500-750 mg qd (once daily) (maximum daily dose 1 g) [Alternatively, ethambutol doses according to the guideline dose of 15 mg / kg per day may be used]. Treatment group B: Bedaquiline ** + Clarithromycin 400 mg twice daily + Ethambutol 500-750 mg qd (once daily) (maximum daily dose of 1 g) [Alternatively, ethambutol doses according to the guideline dose of 15 mg / kg per day may be used]. * Participants may receive rifampicin (450 mg once daily, maximum daily dose 600 mg). If rifampicin is ineffective or unavailable, rifabutin (300 mg once daily) should be considered. ** Participants will receive bedaquiline as follows: Weeks 1-2: 400 mg (four tablets of 100 mg) qd. Weeks 3 to 48: 200 mg (two 100 mg tablets) twice weekly (at least 48 hours between doses).
[0092] Subjects were randomly assigned to one of two treatment groups based on a computer-generated randomization schedule prepared in advance of the study by or under the supervision of the sponsor, with randomization balanced by the use of randomly permuted blocks.
[0093] All study medications will be administered orally, and medication should be administered at approximately the same time each day.
[0094] The study consists of a screening period (1 month), a baseline visit (Day 1), a 12-month open-label treatment period (Day 1-Week 48), and a 3-month follow-up period (Week 48-Week 60). The total study duration for each subject will be approximately 15 weeks. Participants will return for study visits every other week for the first 3 months, and then at Weeks 16, 20, 24, 32, 40, 48, and 60.
[0095] All subjects will be followed up to 120 weeks after baseline to collect long-term safety and tolerability, pharmacokinetics, TB treatment outcomes, and antimycobacterial information. Subjects who prematurely discontinue study drug and study procedures will be followed for survival up to 120 weeks after baseline unless they withdraw from the study (e.g., withdraw consent / acknowledgement). The total study duration (including treatment and follow-up phases, but excluding the screening phase) is 120 weeks for each participant. The study will be considered completed at the last visit of the last participant enrolled in the study.
[0096] To improve the bioavailability of bedaquiline, it should be administered with food, as this can improve bioavailability by approximately two-fold.
[0097] Sample size determination Based on the results of two clinical trials (Phase 2 and Phase 3) of amikacin liposomal inhalation suspension in similar populations, the rifamycin-containing regimen in this study is expected to have a sputum culture conversion rate estimated to be equal to 10% after 24 weeks of treatment.
[0098] A sample size of 180 participants (Group A: 90 in the bedaquiline-containing regimen, Group B: 90 in the rifamycin-containing regimen) had approximately 90% power to demonstrate a 20% difference in the proportion of participants with sputum conversion at week 24 based on a chi-square test (5% two-sided significance level) for the intention-to-treat (ITT) population.
[0099] Statistical analysis: Sputum culture conversion rates in MGIT at week 24 will be compared using a chi-squared test (5% two-sided significance level). Participants missing sputum samples (i.e., three consecutive negative sputum cultures collected at least 25 days apart) that impact the ability to assess sputum culture conversion will be attributed to non-converters in the analysis. Participants who require a change in treatment regimen to an individualized regimen will also be considered non-converters. Contaminated sputum cultures or culture failures occurring between two negative cultures will be interpreted as "not available" and disregarded for the assessment of three consecutive negative cultures.
Claims
1. 1. A pharmaceutical formulation for use in a method of treating a disease (e.g., a pulmonary disease) associated with an NTM (e.g., more specifically, a MAC) in a patient, comprising: The method comprises: (i) a first drug component which is bedaquiline; and (ii) a second drug moiety which is a macrolide (e.g., clarithromycin or azithromycin); and (iii) a third drug component which is ethambutol; and and administering to said patient an effective amount of a combination of pharmaceutical ingredients comprising (e.g., consisting of) - 400 mg of bedaquiline administered once daily during weeks 1-2 and 200 mg of bedaquiline administered twice weekly (with at least 72 hours between doses) during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); or - 400 mg of bedaquiline administered once daily during weeks 1-2 and 100 mg of bedaquiline administered five times per week during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); A specific regimen including The pharmaceutical formulation comprises the first drug component, the second drug component, and / or a third drug component.
2. said administering to said patient 2. The pharmaceutical formulation of claim 1, comprising a specific regimen comprising 400 mg of bedaquiline administered once daily during weeks 1-2 and 100 mg of bedaquiline administered 5 times per week during weeks 3-48.
3. 1. A drug component combination product comprising (e.g. consisting of) a first drug component which is bedaquiline, a second drug component which is a macrolide (e.g. clarithromycin or azithromycin), and a third drug component which is ethambutol for use in the treatment of a disease associated with nontuberculous mycobacteria (NTM), said combination product comprising: - 400 mg of bedaquiline administered once daily during weeks 1-2 and 200 mg of bedaquiline administered twice weekly (with at least 72 hours between doses) during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); or - 400 mg of bedaquiline administered once daily during weeks 1-2 and 100 mg of bedaquiline administered five times per week during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); A combination product administered in a specific regimen including:
4. The combination product comprises:
4. The combination product according to claim 3, administered in a specific regimen comprising 400 mg of bedaquiline once daily from weeks 1 to 2 and 200 mg of bedaquiline twice weekly from weeks 3 to 48, with at least 72 hours between doses.
5. The regimen comprises: A pharmaceutical formulation according to claim 1 or claim 2 or a combination product according to claim 3 or claim 4 comprising administration of a macrolide, for example 800 mg / day in the case of clarithromycin, e.g. 400 mg twice a day (i.e. 400 mg "bid"), and 250 mg / day in the case of azithromycin.
6. The regimen comprises:
6. A pharmaceutical formulation or combination product according to claim 5, comprising the administration of ethambutol using a dosage of 500 to 750 mg qd or a maximum daily dose of 1 g.
7. A pharmaceutical formulation according to any one of claims 1, 2, 5 to 6 or a combination product according to any one of claims 3 to 6, wherein said bedaquiline is administered in the form of bedaquiline fumarate.
8. A pharmaceutical formulation according to any one of claims 1, 2, 5 to 7 or a combination product according to any one of claims 3 to 7, wherein the macrolide is clarithromycin.
9. 9. The pharmaceutical formulation or combination product of claim 8, wherein the clarithromycin is administered in the form of clarithromycin or a salt thereof.
10. A pharmaceutical formulation according to any one of claims 1, 2, 5 to 9 or a combination product according to any one of claims 3 to 9, wherein the ethambutol is administered in the form of ethambutol hydrochloride.
11. A pharmaceutical formulation according to any one of claims 1, 2, 5 to 10 or a combination product according to any one of claims 3 to 10, wherein the first, second and third drug components are the only drug components in the combination.
12. A pharmaceutical formulation according to any one of claims 1, 2, 5 to 11 or a combination product according to any one of claims 3 to 11, wherein the regimen is safe and effective (e.g. in the treatment of diseases associated with NTM such as PAC-PD).
13. The pharmaceutical formulation according to any one of claims 1, 2, 5 to 12 or the combination product according to any one of claims 3 to 12, wherein the disease associated with nontuberculous mycobacteria (NTM) is NTM-PD.
14. The pharmaceutical formulation or combination product of claim 13, wherein the disease is NTM-PD, in which the NTM isolates are not macrolide resistant.
15. The pharmaceutical formulation of any one of claims 1, 2, 5-14 or the combination product of any one of claims 3-14, wherein the first drug component, the second drug component, and / or the third drug component are administered as separate pharmaceutical formulations.
16. A combination product according to any one of claims 3 to 15 (dependent on claim 3), wherein the antibacterial combinations described herein may be administered simultaneously, sequentially or substantially simultaneously.
17. A process for preparing a combination product according to any one of claims 3 to 16, comprising the steps of: - associating each of the components of the combination product (e.g. as separate pharmaceutical formulations), co-packaging (e.g. as a kit of parts), or indicating that the intended use is in combination (with other components); and / or - bringing each of said components into association in the preparation of a pharmaceutical formulation comprising said components.
18. A pharmaceutical formulation for use in the treatment of a disease associated with nontuberculous mycobacteria (NTM), comprising bedaquiline, said bedaquiline being administered in combination with a macrolide (clarithromycin) and ethambutol; - 400 mg of bedaquiline administered once daily during weeks 1-2 and 200 mg of bedaquiline administered twice weekly (with at least 72 hours between doses) during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); or - 400 mg of bedaquiline administered once daily during weeks 1-2 and 100 mg of bedaquiline administered five times per week during weeks 3-24 (and optionally up to week 48, i.e., weeks 3-48); The pharmaceutical preparation is administered in a specific regimen comprising:
19. The bedaquiline 19. The pharmaceutical formulation of claim 18, administered in a specific regimen comprising administering 400 mg of bedaquiline once daily from weeks 1 to 2 and 200 mg of bedaquiline twice weekly from weeks 3 to 48, with at least 72 hours between doses.
20. The macrolide is 20. The pharmaceutical formulation of claim 18 or claim 19, administered in a specific regimen comprising -800 mg / day of clarithromycin, for example 400 mg twice a day (i.e. 400 mg "bid").
21. The ethambutol is A pharmaceutical formulation according to any one of claims 18 to 20, administered in a specific regimen comprising administration of 500 to 750 mg qd or a maximum daily dose of 1 g of ethambutol (e.g. ethambutol hydrochloride).
22. The pharmaceutical formulation according to any one of claims 18 to 21, wherein the bedaquiline is administered in the form of bedaquiline fumarate.
23. A pharmaceutical formulation according to any one of claims 18 to 22, wherein the bedaquiline, the macrolide and the ethambutol are the only drug components administered.
24. The pharmaceutical formulation of any one of claims 18 to 23, wherein the regimen is safe and effective (eg, in the treatment of a disease associated with NTM, such as PAC-PD).
